238 related articles for article (PubMed ID: 27840857)
1. Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.
Blum K; Febo M; Badgaiyan RD
Austin Addict Sci; 2016; 1(2):. PubMed ID: 27840857
[TBL] [Abstract][Full Text] [Related]
2. Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Baron D; Braverman ER; Dushaj K; Li M; Demetrovics Z; Badgaiyan RD
J Reward Defic Syndr Addict Sci; 2017; 3(1):3-13. PubMed ID: 28804788
[TBL] [Abstract][Full Text] [Related]
3. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
4. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
5. Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term.
Blum K; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Thanos PK; Demetrovics Z; Febo M
J Reward Defic Syndr Addict Sci; 2016; 2(1):14-21. PubMed ID: 28317038
[TBL] [Abstract][Full Text] [Related]
6. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
Gold MS; Baron D; Bowirrat A; Blum K
J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
[TBL] [Abstract][Full Text] [Related]
7. Death by Opioids: Are there non-addictive scientific solutions?
Downs BW; Blum K; Baron D; Bowirrat A; Lott L; Brewer R; Boyett B; Siwicki D; Roy AK; Podesta A; Badgaiyan S; Hajela R; Fried L; Badgaiyan RD
J Syst Integr Neurosci; 2019 Jun; 5():. PubMed ID: 31824737
[TBL] [Abstract][Full Text] [Related]
8. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
[TBL] [Abstract][Full Text] [Related]
9. Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Blum K; Febo M; Thanos PK; Baron D; Fratantonio J; Gold M
Mol Neurobiol; 2015 Dec; 52(3):1862-1869. PubMed ID: 25750061
[TBL] [Abstract][Full Text] [Related]
10. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
[TBL] [Abstract][Full Text] [Related]
11. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
[TBL] [Abstract][Full Text] [Related]
12. Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS).
Blum K; Giordano J; Baron D; McLaughlin T; Badgaiyan RD
J Syst Integr Neurosci; 2020; 8():. PubMed ID: 36407844
[TBL] [Abstract][Full Text] [Related]
13. Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause.
Blum K; Gold MS; Jacobs W; McCall WV; Febo M; Baron D; Dushaj K; Demetrovics Z; Badgaiyan RD
Front Biosci (Landmark Ed); 2017 Mar; 22(8):1247-1288. PubMed ID: 28199203
[TBL] [Abstract][Full Text] [Related]
14. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
[TBL] [Abstract][Full Text] [Related]
15. Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.
Duquette LL; Mattiace F; Blum K; Waite RL; Boland T; McLaughlin T; Dushaj K; Febo M; Badgaiyan RD
Clin Med Rev Case Rep; 2016; 3(5):. PubMed ID: 29214221
[TBL] [Abstract][Full Text] [Related]
16. Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.
Blum K; Febo M; Badgaiyan RD; Braverman ER; Dushaj K; Li M; Demetrovics Z
Curr Pharm Des; 2016; 22(38):5837-5854. PubMed ID: 27510492
[TBL] [Abstract][Full Text] [Related]
17. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
[TBL] [Abstract][Full Text] [Related]
18. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.
Blum K; Liu Y; Wang W; Wang Y; Zhang Y; Oscar-Berman M; Smolen A; Febo M; Han D; Simpatico T; Cronjé FJ; Demetrovics Z; Gold MS
Postgrad Med; 2015 Mar; 127(2):232-41. PubMed ID: 25526228
[TBL] [Abstract][Full Text] [Related]
19. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
Chen TJ; Blum K; Chen AL; Bowirrat A; Downs WB; Madigan MA; Waite RL; Bailey JA; Kerner M; Yeldandi S; Majmundar N; Giordano J; Morse S; Miller D; Fornari F; Braverman ER
J Psychoactive Drugs; 2011; 43(2):108-27. PubMed ID: 21858957
[TBL] [Abstract][Full Text] [Related]
20. Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality?
Blum K; Soni D; Badgaiyan RD; Baron D
J Osteopath Med; 2022 Apr; 122(7):333-337. PubMed ID: 35411759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
